Conjunctivitis: Infants ≥2 months, Children, and Adolescents: Ophthalmic:
Ointment: Instill 1/2 inch ribbon into the lower conjunctival sac of affected eye(s) every 3 to 4 hours and at bedtime; increase dosing interval as condition responds. Ointment may be used as an adjunct to the solution; usual duration of treatment: 7 to 10 days
Solution: Instill 1 to 2 drops into the lower conjunctival sac of affected eye(s) every 2 to 3 hours initially; increase dosing interval as condition responds; usual duration of treatment: 7 to 10 days
Trachoma: Infants ≥2 months, Children, and Adolescents: Ophthalmic: Solution: Instill 2 drops into the conjunctival sac of affected eye(s) every 2 hours; must be used in conjunction with systemic therapy
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
(For additional information see "Sulfacetamide (ophthalmic): Drug information")
Conjunctivitis, other superficial ocular infections: Note: Taper dose by increasing dosage time interval as condition responds; usual duration of treatment: 7 to 10 days:
Ophthalmic ointment: Apply ~1/2-inch ribbon into the conjunctival sac of affected eye(s) every 3 to 4 hours and at bedtime.
Ophthalmic solution: Instill 1 to 2 drops into the conjunctival sac(s) of affected eye(s) every 2 to 3 hours.
Trachoma: Ophthalmic solution: Instill 2 drops into the conjunctival sac(s) of affected eye(s) every 2 hours; must be used in conjunction with systemic therapy.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Ointment, Ophthalmic, as sodium:
Generic: 10% (3.5 g)
Solution, Ophthalmic, as sodium:
Bleph-10: 10% (5 mL)
Generic: 10% (5 mL, 15 mL)
Yes
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Ophthalmic, as sodium:
Sodium Sulamyd: 10% ([DSC])
Generic: 10% (15 mL)
For topical application to the eye only; not for injection. Avoid contact of tube or bottle tip with skin or eye. Apply gentle pressure to lacrimal sac during and immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration, to decrease systemic absorption of ophthalmic drops (Urtti 1993; Zimmerman 1982).
Ophthalmic: For topical ophthalmic use only; not for injection. Avoid contact of tube or bottle tip with skin or eye.
Ointment: May be used as an adjunct to the ophthalmic solution.
Solution: Apply finger pressure to lacrimal sac during and for 1 to 2 minutes after instillation of solution to decrease risk of absorption and systemic effects. For the treatment of trachoma, use must be in conjunction with systemic therapy.
Solution: Store at 8°C to 25°C (46°F to 77°F); protect from light. Darkened solutions should not be used.
Ointment: Store at 20°C to 25°C (68°F to 77°F).
Ophthalmic: Treatment of conjunctivitis and other superficial ocular infections due to susceptible organisms (Ointment; solution: FDA approved in ages ≥2 months and adults); adjunctive treatment with systemic sulfonamides for therapy of trachoma (Solution: FDA approved in ages ≥ 2 months and adults)
Bleph-10 may be confused with Blephamide
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not defined.
Cardiovascular: Edema
Hypersensitivity: Hypersensitivity reaction
Neuromuscular & skeletal: Systemic lupus erythematosus
Ophthalmic: Burning sensation of eyes, conjunctival hyperemia, conjunctivitis, corneal ulcer, eye irritation, stinging of eyes
Hypersensitivity to sulfonamides or any component of the formulation.
Documentation of allergenic cross-reactivity for sulfonamides is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.
Concerns related to adverse effects:
• Blood dyscrasias: Severe reactions (rare fatalities), including agranulocytosis, aplastic anemia, and other blood dyscrasias, have occurred with sulfonamides (regardless of route). Discontinue at the first sign of serious reaction.
• Dermatologic reactions: Severe reactions (rare fatalities), including Stevens-Johnson syndrome and toxic epidermal necrolysis, have occurred with sulfonamides (regardless of route). Discontinue at first sign of rash.
• Hepatic necrosis: Fatalities (rare) associated with fulminant hepatic necrosis have occurred with sulfonamides (regardless of route). Discontinue at first sign of serious reaction.
• Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling; however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.
• Superinfection: Prolonged use may lead to overgrowth of nonsusceptible organisms, including fungi. If superinfection is suspected, institute appropriate alternative therapy.
Other warnings/precautions:
• Administration: Do not use concurrently with silver preparations.
• Appropriate use: For topical application to the eye only; not for injection. To avoid contamination, do not touch tip of container to any surface.
• Efficacy: May be inactivated by purulent exudates containing PABA.
None known.
There are no known significant interactions.
Animal reproduction studies have not been conducted. Use of systemic sulfonamides during pregnancy may cause kernicterus in the newborn.
Response to therapy
Interferes with bacterial growth by inhibiting bacterial folic acid synthesis through competitive antagonism of PABA
Onset of action: Improvement of conjunctivitis is usually seen within 3 to 6 days
Ointment (Sulfacetamide Sodium Ophthalmic)
10% (per gram): $18.82
Solution (Bleph-10 Ophthalmic)
10% (per mL): $33.51
Solution (Sulfacetamide Sodium Ophthalmic)
10% (per mL): $3.71 - $4.07
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
